RICHMOND, Va.--(BUSINESS WIRE)--Insmed Incorporated (NASDAQ: INSM), a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs, today announced results for the three and twelve month periods ended December 31, 2006.
